(Reuters) – Eli Lilly and Co said on Thursday the U.S. Food and Drug Administration had declined to approve the company’s experimental Alzheimer’s disease treatment, citing limited number of patients with at least 12 months of drug exposure data provided in the submission.
(Reporting by Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)
